---
title: "5 Healthcare Stocks Set to Join the Russell 3000"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287611352.md"
description: "FTSE Russell has announced preliminary changes to the Russell 3000 Index, adding several healthcare stocks including Ocugen, Senseonics, Nektar Therapeutics, Agenus, and CytomX Therapeutics. These additions can enhance visibility and attract investment from ETFs. Ocugen has surged over 140% in the past year, while Nektar Therapeutics has jumped over 250%. Analysts rate these stocks favorably, with Ocugen showing the highest upside potential at over 760%."
datetime: "2026-05-26T09:22:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287611352.md)
  - [en](https://longbridge.com/en/news/287611352.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287611352.md)
---

# 5 Healthcare Stocks Set to Join the Russell 3000

FTSE Russell has released its preliminary changes for the Russell 3000 Index ahead of the official rebalancing on June 26, putting several healthcare and biotech stocks in focus. The Russell 3000 is a broad U.S. stock market index widely tracked by ETFs and institutional investors.

### Meet Samuel – Your Personal Investing Prophet

-   Start a conversation with TipRanks' trusted, data-backed investment intelligence
-   Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds

For smaller biotech companies, joining the Russell 3000 can increase visibility and attract buying from ETFs and index-tracking funds. Meanwhile, stocks removed from the benchmark can face selling pressure as funds rebalance their portfolios.

## **Expected Additions**

-   **Ocugen (OCGN)** – A biotechnology company developing gene therapies for diseases that cause blindness. OCGN stock has surged more than 140% over the past year and currently carries a Moderate Buy rating from Wall Street analysts.
-   **Senseonics (SENS)** – A medical technology company focused on implantable glucose monitoring systems for diabetes patients. SENS shares have gained nearly 90% over the past 12 months and currently hold a Moderate Buy rating.
-   **Nektar Therapeutics (NKTR)** – A clinical-stage biotech company developing treatments for autoimmune diseases. The stock has jumped more than 250% over the past year and currently carries a Moderate Buy rating.
-   **Agenus (AGEN)** – An immunotherapy company focused on cancer treatments. AGEN stock is up roughly 70% over the past year and currently has a Strong Buy rating.
-   **CytomX Therapeutics (CTMX)** – A biotech firm developing targeted cancer therapies. CTMX shares have climbed about 40% over the past year and currently carry a Moderate Buy rating.

## **Wall Street's Take on These Stocks**

Using the TipRanks Stock Comparison Tool, Ocugen, CytomX Therapeutics, and iBio currently carry Strong Buy ratings from Wall Street analysts. Among the stocks shown above, Ocugen offers the highest upside potential at more than 760%, while Assertio has the lowest projected upside at about 3% despite being the top year-to-date performer with gains of over 158%.

### Related Stocks

- [AGEN.US](https://longbridge.com/en/quote/AGEN.US.md)
- [OCGN.US](https://longbridge.com/en/quote/OCGN.US.md)
- [SENS.US](https://longbridge.com/en/quote/SENS.US.md)
- [NKTR.US](https://longbridge.com/en/quote/NKTR.US.md)
- [CTMX.US](https://longbridge.com/en/quote/CTMX.US.md)
- [VTHR.US](https://longbridge.com/en/quote/VTHR.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IWV.US](https://longbridge.com/en/quote/IWV.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBIO.US](https://longbridge.com/en/quote/IBIO.US.md)
- [ASRT.US](https://longbridge.com/en/quote/ASRT.US.md)
- [00847G804.US](https://longbridge.com/en/quote/00847G804.US.md)

## Related News & Research

- [Is Nektar (NKTR) Betting Its Immunology Future on Rezpegaldesleukin’s Ambitious ZENITH-AD Phase 3 Program?](https://longbridge.com/en/news/289087155.md)
- [Ocugen Advances Late-Stage Gene Therapies, Bolsters Cash Runway](https://longbridge.com/en/news/285244765.md)
- [Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage](https://longbridge.com/en/news/272737139.md)
- [BUZZ-Ocugen plunges after $115 million convertible bonds offering, bigger loss](https://longbridge.com/en/news/285252501.md)
- [Gene therapy firm Ocugen's Q1 revenue beats, extends cash runway to 2028](https://longbridge.com/en/news/285208944.md)